Mieles L, Ye Y, Luo Y, Kobayashi T, Li S F, Niekrasz M, Kosanke S, Smith D, Cooper D K
Oklahoma Transplantation Institute, Baptist Medical Center, Oklahoma City, OK 73112, USA.
Transplantation. 1995 Jun 27;59(12):1670-6. doi: 10.1097/00007890-199506270-00005.
Auxiliary liver transplantation has been performed in the baboon using allografts (n = 8) and concordant xenografts from donor African green monkeys (n = 8). The native portal vein was ligated in all cases and the native common bile duct was ligated in 5 cases. The immunosuppressive therapy used was identical in both the allografts and xenografts and consisted of triple drug therapy (cyclosporine, cyclophosphamide, and methylprednisolone), all at dosages consistent with clinical use. During the determination of the surgical technique to be applied, there were 5 early failures (3 allografts, 2 xenografts), and 2 deaths at 10 and 20 days from multiorgan failure and sepsis, respectively (xenografts). The remaining 9 baboons (5 allografts, 4 xenografts) were electively euthanized at 16-62 days (allografts) and 35-120 days (xenografts). Hyperacute rejection or antibody-mediated rejection was not seen in the grafted livers. Episodes of acute cellular rejection occurred in the majority of animals within the first 30 days and recurred in the longer-term survivors, but could be controlled by bolus therapy with intravenous methylprednisolone. Satisfactory donor liver function was confirmed using a number of tests, including scintigraphy in 3 cases. We conclude that auxiliary liver transplantation using a closely related donor species is feasible in baboons and might be extended to humans with terminal liver failure. A baboon-to-man auxiliary liver graft may serve as a "bridge" until either a human cadaver donor liver became available or native liver function recovers in patients with fulminant hepatic failure.
在狒狒身上进行了辅助肝移植,使用了同种异体移植物(n = 8)和来自供体非洲绿猴的协调性异种移植物(n = 8)。所有病例均结扎了肝门静脉,5例结扎了肝总胆管。同种异体移植物和异种移植物使用的免疫抑制疗法相同,均采用三联药物疗法(环孢素、环磷酰胺和甲基泼尼松龙),所有药物剂量均与临床使用一致。在确定要应用的手术技术过程中,有5例早期失败(3例同种异体移植物,2例异种移植物),2例分别在术后10天和20天因多器官功能衰竭和败血症死亡(异种移植物)。其余9只狒狒(5例同种异体移植物,4例异种移植物)分别在术后16 - 62天(同种异体移植物)和35 - 120天(异种移植物)被选择性安乐死。移植肝脏未出现超急性排斥反应或抗体介导的排斥反应。大多数动物在术后前30天内发生急性细胞排斥反应,长期存活者会复发,但可通过静脉注射甲基泼尼松龙推注疗法控制。通过多项检查证实供肝肝功能良好,包括3例的闪烁扫描。我们得出结论,使用密切相关供体物种进行辅助肝移植在狒狒身上是可行的,可能会扩展到终末期肝衰竭患者。狒狒到人的辅助肝移植可作为“桥梁”,直到有人类尸体供体肝脏可用或暴发性肝衰竭患者的肝功能恢复。